Using in vitro assays, the authors proved that the secreted FHR5 was biologically active by using the hemolytic assay to show that primary glioblastoma cell-secreted FHR5 exhibited dose-dependent inhibition of sheep erythrocyte lysis. Here, CFHR5 is linked to glioblastoma.